$12.325
+0.505 (+4.10%)收盘时
IART 资讯
IART 事件
Company Sees Q4 Revenue of $413M-$433M
Sees Q4 revenue $413M-$433M, consensus $432.21M. Q4 guidance represents a decline of -5.2% to -0.5% and an organic decline of (5.1%) to (0.4%). Stuart Essig, Chairman and CEO, said, "Our updated outlook reflects both the recovery timeline in Cincinnati and more measured expectations for portions of our Tissue Reconstruction business. We are focused on executing against these challenges while continuing to support our customers, advance key product launches and returns, and strengthen the business for more consistent long-term growth."
Company Sees Q4 Revenue of $413M-$433M
Sees Q4 revenue $413M-$433M, consensus $432.21M. Q4 guidance represents a decline of -5.2% to -0.5% and an organic decline of (5.1%) to (0.4%). Stuart Essig, Chairman and CEO, said, "Our updated outlook reflects both the recovery timeline in Cincinnati and more measured expectations for portions of our Tissue Reconstruction business. We are focused on executing against these challenges while continuing to support our customers, advance key product launches and returns, and strengthen the business for more consistent long-term growth."
Integra Lowers FY26 Revenue Outlook to $1.634B-$1.654B
Integra lowers FY26 revenue view to $1.634B-$1.654B from $1.654B-$1.695B. Consensus is for FY26 EPS $2.38 and for revenue $1.66B. FY26 revenue guidance represents a reported growth of (0.1%)-1.2% and organic growth of (-0.3%) to (0.9%). The Company continues to expect operating cash flow of approximately $190M-$200M for the full year. These expectations are consistent with the preliminary results and updated guidance provided on October 2. The updated Q4 and full-year outlook reflects the expected revenue impact of the Cincinnati disruption, an updated outlook for Tissue Reconstruction performance, and a consistent outlook for Specialty Surgery. The adjusted earnings per diluted share outlook also reflects business interruption insurance recoveries for lost revenue related to the Cincinnati disruption and incremental interest expense associated with the refinancing.
Company Reports Q3 Revenue of $411.2M
Reports Q3 revenue $411.2M, consensus $412.1M. "Our Q3 performance reflected mixed results across our portfolio, with stronger performance in Specialty Surgery partially offset by a $7M impact from the Cincinnati disruption and softer-than-expected results in Tissue Reconstruction. We delivered results within our guidance ranges, generated strong cash flow, reduced leverage, and subsequently completed our debt refinancing," said Stuart Essig, Chairman and CEO.
Integra Lowers FY26 Revenue Outlook to $1.634B-$1.654B
Integra lowers FY26 revenue view to $1.634B-$1.654B from $1.654B-$1.695B. Consensus is for FY26 for revenue $1.66B. FY26 revenue guidance represents a reported growth of (0.1%)-1.2% and organic growth of (-0.3%) to (0.9%). The Company continues to expect operating cash flow of approximately $190M-$200M for the full year. These expectations are consistent with the preliminary results and updated guidance provided on October 2. The updated Q4 and full-year outlook reflects the expected revenue impact of the Cincinnati disruption, an updated outlook for Tissue Reconstruction performance, and a consistent outlook for Specialty Surgery. The adjusted earnings per diluted share outlook also reflects business interruption insurance recoveries for lost revenue related to the Cincinnati disruption and incremental interest expense associated with the refinancing.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。